#China #Shanghai #HAE #Argo Biopharma #BW-20805

Argo Biopharma to Present Phase II Results for BW-20805

Argo Biopharmaceutical Co., Ltd., a noteworthy player in the realm of RNA interference (RNAi) therapeutics, is on the cusp of revealing significant advancements at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting set for February 27-March 2, 2026. The firm has been chosen to present interim findings from its Phase II clinical trial focusing on BW-20805, a compelling investigational small interfering RNA (siRNA) therapy aimed at treating hereditary angioedema (HAE).

Overview of BW-20805

BW-20805 represents a novel approach in managing hereditary angioedema, a rare but serious genetic disorder that can lead to episodes of severe swelling in various parts of the body. This therapeutic candidate is designed to inhibit prekallikrein (PKK), a pivotal protein implicated in the pathophysiology of HAE attacks. By targeting PKK, BW-20805 holds the promise of not only preventing attacks but also delivering sustained long-term efficacy.

The excitement surrounding the presentation lies in its classification as a late-breaking abstract, a testament to the compelling nature of the data that Argo Biopharma will share with the scientific community. Dr. Dongxu Shu, co-founder and CEO, emphasized the importance of this opportunity, stating that it recognizes the strength of the evidence amassed in support of BW-20805. He highlighted expectation for sustained reductions in HAE attack rates and a commendable safety profile.

Key Results from the Study

The open-label study, which will be presented under the title "Significant HAE Attack Reduction with BW-20805, a Long-Acting Prophylactic Injection-An Ongoing Phase 2 Study in Adults with Hereditary Angioedema", showcases groundbreaking results:

• - A staggering 100% reduction in the time-normalized HAE attack rate for patients receiving a 600 mg Q24W regimen.
• - In the 300 mg Q24W and 300 mg Q12W groups, attack rates dropped by 89% and 87% respectively.
• - Notably, 80% of the treated patients remained attack-free during the observation period.

Additionally, the study reported profound decreases in plasma PKK levels, surpassing 92% reduction in the pooled 300 mg groups. As of Day 169, reductions sustained at 98% and 97% in the respective dosing groups, showcasing BW-20805's durability as a treatment option.

Safety has also been a focal point in these investigations. The findings indicate that BW-20805 was generally well tolerated, with only mild, transient injection-site reactions reported, and no serious adverse events noted throughout the study.

Understanding Hereditary Angioedema (HAE)

Hereditary angioedema is characterized by unpredictable episodes of swelling, which can be distressing and, in severe instances, life-threatening. It is estimated to occur in approximately 1.5 individuals per 100,000 worldwide. Current treatment regimens necessitate frequent dosing, thus the necessity for innovative long-acting therapies is paramount.

BW-20805 presents a novel solution to this pressing need by selectively targeting the mRNA of hepatic PKK to inhibit its expression, potentially transforming the landscape of HAE management.

Future Directions for Argo Biopharma

As Argo Biopharma gears up for the presentation at the AAAAI Annual Meeting, it marks a significant step forward in the pursuit of groundbreaking therapeutic options for hereditary angioedema. The ongoing evaluation of BW-20805 seeks to solidify its standing as a potential best-in-class therapeutic choice for patients requiring prophylactic care.

Argo Biopharma remains dedicated to advancing RNAi therapeutics and is expanding its portfolio, with seven RNAi candidates currently under clinical development. For additional information about their ongoing work and latest insights, visit www.argobiopharma.com.

In summary, the forthcoming presentation at the AAAAI Annual Meeting is eagerly anticipated, as it could herald a new era of treatment possibilities for those affected by HAE.